Medchemexpress LLC Rebastinib (DCC-2036) | 1020172-07-9 | 99.84% | 200 MG

Supplier:  Medchemexpress LLC HY13024200MG

Rebastinib is an orally active, non-ATP-competitive inhibitor that targets Bcr-Abl, including its wild-type and T315I mutant forms. It also demonstrates inhibitory activity against SRC, KDR, FLT3, and Tie-2, while showing minimal activity against c-Kit.

• Orally active.
• Non-ATP-competitive inhibition of Bcr-Abl.
• Effective against wild-type and T315I mutant Bcr-Abl.
• Inhibits other kinases such as SRC, KDR, FLT3, and Tie-2.
• Demonstrates low activity toward c-Kit.
• Potently inhibits both inactive and active forms of ABL1.
• Effective against several common TKI-resistant Bcr-Abl mutants.
• Inhibits proliferation of cells expressing Bcr-Abl and Ph+ cell lines.
• Reduces autophosphorylation of Bcr-Abl and phosphorylation of STAT5.

Catalog No. 50-003-38944